Aspen Aerogels Inc. (ASPN) stock plummeted 27.91% in intraday trading on Wednesday, following the company's release of its fourth-quarter 2024 financial results and disappointing guidance for the first quarter of 2025.
While Aspen Aerogels reported better-than-expected Q4 revenue and earnings, beating analysts' estimates, the market reacted negatively to its weak Q1 2025 guidance. The company provided a Q1 revenue guidance range of $75 million to $95 million, significantly lower than the consensus estimate of $104.22 million. Additionally, its Q1 EPS guidance range of ($0.18) to $0.00 fell short of the consensus estimate of $0.08.
Adding to the stock's decline, Aspen Aerogels also announced that it is halting the construction of its Statesboro manufacturing facility, citing the need to focus resources on its existing operations.